As a surgeon, you always want to provide your patients with the best possible visual outcomes.
However, patients that desire spectacle independence are not always suitable candidates for diffractive trifocal IOLs.To overcome these challenges, many surgeons turn to doré as an affordable way of delivering some extended depth of vision with reduced dysphotopsia.
OcuSenseTM was developed in collaboration with world renowned surgeon, Professor Graham Barrett, to specifically enhance the visual outcomes achieved with doré. OcuSenseTM uniquely extends a patient’s range of vision with a patented non-diffractive optic profile, enabling the depth of field of many presbyopia-correcting IOLs but with no dysphotopsia, short neuroadaptation, reliable outcomes, high patient satisfaction, and improved affordability. OcuSenseTM is a versatile IOL that also enhances patient outcomes when bilateral emmetropia is targeted. Offered on a superior hydrophilic optic platform through the RayOne fully preloaded two-step injector, OcuSenseTM is an enhanced monofocal IOL solution unlike any other.
Improve Your Patient Satisfaction
First Clinical Results With OcuSenseTM
OcuSenseTM was launched in CE mark-accepting countries in October 2020. The following clinical results are from twenty patients in the UK, Spain and Portugal who were implanted bilaterally with OcuSenseTM in the months leading up to the commercial launch.
At one-month postoperative, visual acuity and refractive data showed excellent results.
Early Experience With OcuSenseTM
Dr. Mariano Royo, Director of Ophthalmology at the Hospital San Rafael in Madrid and Director of the Ophthalmic Institute of Madrid, shared his clinical results of 22 eyes of 11 patients implanted with OcuSenseTM at six months post-op and 70 eyes of 35 patients implanted with TECNIS Eyhance (Johnson & Johnson Vision) measured at one-year post-op. Bilateral emmetropia was targeted for all patients in both groups. Figure 1 reports the binocular defocus curve obtained using the best distance correction. A progression of plus and minus lenses in 0.5 D increments was consecutively added (range +3.0 to -5.0 D) to produce defocus after which visual acuity was tested again.
Information for patients
20/20 Near, Intermediate & Distance Vision Is Now Possible
5 Million Eyes Globally Has Been Implanted
Enhance Your Vision For Clear Complete Focus
See Effortless Without Blurry Zones
Discover Brighter & Vivid Colours
Reduce Your Need Wear To Glasses
